A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination. - Wikidata - thesis-toulmin - TriplyDB

A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

http://www.wikidata.org/entity/Q33401609

about

The evolution of poxvirus vaccines A replicating modified vaccinia tiantan strain expressing an avian-derived influenza H5N1 hemagglutinin induce broadly neutralizing antibodies and cross-clade protective immunity in mice AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines The development of an AIDS mucosal vaccine.Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigens Unpolarized release of vaccinia virus and HIV antigen by colchicine treatment enhances intranasal HIV antigen expression and mucosal humoral responses.Attenuation of vaccinia Tian Tan strain by removal of viral TC7L-TK2L and TA35R genes.Deletion of C7L and K1L genes leads to significantly decreased virulence of recombinant vaccinia virus TianTan Defining the objectives of the AIDS vaccine for Asia network: report of the WHO-UNAIDS/Global HIV vaccine enterprise regional consultation on expanding AIDS vaccine research and development capacity in Asia.Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain Replication-Competent Controlled Herpes Simplex Virus.A pilot study comparing the development of EIAV Env-specific antibodies induced by DNA/recombinant vaccinia-vectored vaccines and an attenuated Chinese EIAV vaccine Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys.Enhancing poxvirus vectors vaccine immunogenicity.A novel approach for addressing diseases not yielding to effective vaccination? Immunization by replication-competent controlled virus.Intranasal and oral vaccination with protein-based antigens: advantages, challenges and formulation strategies.Comparison of the replication characteristics of vaccinia virus strains Guang 9 and Tian Tan in vivo and in vitro.HIV/AIDS Vaccine Candidates Based on Replication-Competent Recombinant Poxvirus NYVAC-C-KC Expressing Trimeric gp140 and Gag-Derived Virus-Like Particles or Lacking the Viral Molecule B19 That Inhibits Type I Interferon Activate Relevant HIV-1-Speci Generation of an attenuated Tiantan vaccinia virus by deletion of the ribonucleotide reductase large subunit.

P2860

Q26995905-30810615-BF90-4695-811F-3DD1F3EDB204 Q30357094-2865D6F8-2DB4-4748-8A09-C34E3930DB08 Q30394227-8182BF84-3CE8-4DE3-897B-0DE9FEC8BE65 Q30408103-009E76EE-E620-48B3-A776-1E5E42DCED6B Q33627613-24517B99-42DA-4D67-B2E2-F3F933E0EB07 Q34026061-4DAFB174-D069-49F5-BE0B-FD778B73DA34 Q34171543-92B3B47C-7FE1-4D8F-BF8B-EEB15660AD08 Q34809121-D7A201D2-7863-41EC-9DF2-6345DF323DBF Q35075505-2FB1420B-D3A9-49F1-9062-B8ADCBF19022 Q35099487-48D81474-C323-404B-972B-7E50103B74A3 Q36086213-3B9A3253-76E1-47B3-9C3F-C1AD36BF72CF Q36456552-780D5949-3242-4D96-B432-004159219C8F Q36827361-81409EAD-E657-4E42-87F7-E95305D02DB2 Q36978452-2CABA2E8-55D9-41E8-9E6E-5E3BA8739D9A Q38353693-B89D6BFF-2668-47AC-92BD-DCF90BD69C9D Q38461061-63C81FBF-3070-4869-A188-6642FD4C2B31 Q38993999-56A23307-2E80-4291-BF2F-50B4BC42CFBC Q40339467-0477F8C2-B654-4E61-BE05-E6DCB20071B2 Q42221766-84F1EA8D-0C0E-499C-8257-766CE130C18E

P2860

A novel replication-competent vaccinia vector MVTT is superior to MVA for inducing high levels of neutralizing antibody via mucosal vaccination.

http://www.wikidata.org/entity/Q33401609

description

2009 nî lūn-bûn

@nan

2009 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

name

A novel replication-competent ...... ibody via mucosal vaccination.

@ast

A novel replication-competent ...... ibody via mucosal vaccination.

@en

type

label

A novel replication-competent ...... ibody via mucosal vaccination.

@ast

A novel replication-competent ...... ibody via mucosal vaccination.

@en

prefLabel

A novel replication-competent ...... ibody via mucosal vaccination.

@ast

A novel replication-competent ...... ibody via mucosal vaccination.

@en

P1433

Q33401609-DC127C5B-428A-4820-80FF-F17F8520745E

P1476

Q33401609-9772DCF1-CDC0-474E-A6D9-94043A080046

P2093

Q33401609-0F482995-471D-4BFC-BEB7-3EB589996BBD

Q33401609-1AE8171C-07E5-46CA-A059-A29A6140FA5E

Q33401609-65B7BFAA-B357-4B1B-91D0-8FB428AFB54A

Q33401609-7E7F9DCC-024C-4234-BCBE-8C81C2C9E1B4

Q33401609-885F0130-5E7E-484A-B4AD-5C2D8F1BF2C3

Q33401609-8BDFAD62-5D94-419D-94DB-8267EA8D5B68

Q33401609-AF234BDB-37A4-475D-894F-55CC0C58AFA0

Q33401609-B786B1D0-ED80-47A1-ABBA-AE8669FCF949

Q33401609-C25FDD9E-12C3-4606-A570-7A11B892153F

P2860

Q33401609-06F24697-6B0C-401B-AFFB-30F0A17AA555

Q33401609-0FE70960-50CE-469B-B87F-78318D1DB08C

Q33401609-11D3A9D7-90C6-4878-B608-D03AB8A5D3CD

Q33401609-130D834D-A95F-4ED9-B332-DE8DC5F4304B

Q33401609-1323C7A5-A8FA-461C-8B52-26458D853479

Q33401609-1B207ED7-63A4-4C35-93DF-96DDE2CDAB93

Q33401609-1B3A242D-C8DB-4BF5-B67C-B92421C536CF

Q33401609-1B4F1221-5483-450A-924C-B563A8712872

Q33401609-1D6E05EC-5CEF-4F65-8EA4-94039E62CEBF

Q33401609-23191B1C-14EF-4F3B-B9AA-41EFCF175E85

P304

Q33401609-95FC7437-7B2F-4EDF-991B-96AE72A90CFA

P31

Q33401609-D99C3604-F0D1-4808-883C-5AF5B85F7245

P356

Q33401609-1E6248E0-8FCD-4014-8803-39C6D72646B4

P407

Q33401609-7FA254ED-A388-41B1-B3BF-BDB701652FFE

P433

Q33401609-F1B5A82D-2CF2-4C96-BE1A-6498CD50F8F8

P478

Q33401609-21B93ACD-A748-44D0-AC02-99879473EABB

P50

Q33401609-752CA709-96A8-4DF7-A68D-F909D3EFB4EF

Q33401609-D3CFF822-ACBD-474E-8300-CD1A71FB037A

P577

Q33401609-EB41939A-4CD9-4B56-9110-E997ECCCCF26

P5875

Q33401609-119A9C45-E9E7-4118-BE69-91F10E4D51D9

P698

Q33401609-30493213-A84D-4761-93AA-8BA30689B546

P921

Q33401609-018DE6D6-719E-4E7D-962C-A2CF1C2BC09A

P932

Q33401609-13A8DC6D-8026-4C72-85EC-F27C332F9FD3

P356

JOURNAL.PONE.0004180

P1433

P1476

A novel replication-competent ...... tibody via mucosal vaccination

@en

P2093

Bin Lu

http://www.w3.org/2001/XMLSchema#string

Haibo Wang

http://www.w3.org/2001/XMLSchema#string

Ke Zhuang

http://www.w3.org/2001/XMLSchema#string

Linqi Zhang

http://www.w3.org/2001/XMLSchema#string

Po Tian

http://www.w3.org/2001/XMLSchema#string

Qing Fang

http://www.w3.org/2001/XMLSchema#string

Tingting Shen

http://www.w3.org/2001/XMLSchema#string

Wenbo Yu

http://www.w3.org/2001/XMLSchema#string

Xiaoxing Huang

http://www.w3.org/2001/XMLSchema#string

P2860

The Future of Smallpox Vaccination: is MVA the key?

Smallpox containment updated: considerations for the 21st century.

The attenuation of vaccinia Tian Tan strain by the removal of the viral M1L-K2L genes.

Recombinant modified vaccinia virus Ankara-based vaccine induces protective immunity in mice against infection with influenza virus H5N1.

Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice

Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein.

Recombinant modified vaccinia virus Ankara expressing the spike glycoprotein of severe acute respiratory syndrome coronavirus induces protective neutralizing antibodies primarily targeting the receptor binding region.

Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara

Modified vaccinia Ankara: potential as an alternative smallpox vaccine.

Poxvirus expression vectors.

P304

e4180

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0004180

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23807598

http://www.w3.org/2001/XMLSchema#string

P698

19159014

http://www.w3.org/2001/XMLSchema#string

P921

P932

2613559

http://www.w3.org/2001/XMLSchema#string